Hypertension, Vol 17, 107-115, Copyright © 1991 by American Heart Association
NE Rhaleb, S Telemaque, N Rouissi, S Dion, D Jukic, G Drapeau and D Regoli
Thirty-seven compounds were tested as antagonists of kinin B2- and B1-
receptors to identify the chemical changes required to obtain antagonism,
improve antagonist affinity, and eliminate residual agonistic activities.
Apparent affinity of antagonists was evaluated in terms of pA2 on the
rabbit jugular vein, the dog carotid and renal arteries, the hamster
urinary bladder, the guinea pig ileum, the rat vas deferens, the guinea pig
trachea, and the rabbit aorta, using bradykinin and desArg9-bradykinin as
B2- and B1-receptor activators. Replacement of Pro7 of bradykinin with
D-Phe leads to antagonism; substitution of Pro3 by Hyp and extension of the
peptide chain at the N- terminal with a D-Arg residue improves the affinity
of antagonists; acetylation of N-terminal amine function reduces residual
agonistic activity; these changes, combined with the replacement of Phe8 by
Leu as in Ac-D-Arg[Hyp3,D-Phe7,Leu8]-bradykinin, led to potent full B2-
receptor antagonists. Affinity of antagonists differs markedly between
highly sensitive (rabbit jugular vein, dog carotid and renal artery),
moderately sensitive (hamster urinary bladder, guinea pig ileum, and rat
vas deferens), and insensitive preparations (the guinea pig trachea) in
which antagonists act as potent stimulants. High concentrations of
antagonists block bradykinin completely in the rabbit jugular vein but not
in the guinea pig ileum, suggesting that kinins stimulate the moderately
sensitive tissues by two mechanisms, of which only one is blocked by
antagonists. It thus appears that kinins act on various B2-receptor
subtypes or by different action mechanisms.
ARTICLES
Structure-activity studies of bradykinin and related peptides. B2- receptor antagonists
Medical School, University of Sherbrooke, Quebec, Canada.
This article has been cited by other articles:
![]() |
T. C. Peterson, M. R. Peterson, H. A. Robertson, M. During, and M. Dragunow Selective Down-Regulation of c-jun Gene Expression by Pentoxifylline and c-jun Antisense Interrupts Platelet-Derived Growth Factor Signaling: Pentoxifylline Inhibits Phosphorylation of c-Jun on Serine 73 Mol. Pharmacol., June 1, 2002; 61(6): 1476 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Houle, J.-F. Larrivee, M. Bachvarova, J. Bouthillier, D. R. Bachvarov, and F. Marceau Antagonist-Induced Intracellular Sequestration of Rabbit Bradykinin B2 Receptor Hypertension, June 1, 2000; 35(6): 1319 - 1325. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Emanueli, E. Fink, A. F. Milia, M. B. Salis, M. Conti, M. P. Demontis, and P. Madeddu Enhanced Blood Pressure Sensitivity to Deoxycorticosterone in Mice With Disruption of Bradykinin B2 Receptor Gene Hypertension, June 1, 1998; 31(6): 1278 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Madeddu, M. V. Varoni, D. Palomba, C. Emanueli, M. P. Demontis, N. Glorioso, P. Dessi-Fulgheri, R. Sarzani, and V. Anania Cardiovascular Phenotype of a Mouse Strain With Disruption of Bradykinin B2-Receptor Gene Circulation, November 18, 1997; 96(10): 3570 - 3578. [Abstract] [Full Text] |
||||
![]() |
F. Gobeil, W. Neugebauer, C. Filteau, D. Jukic, S. N. Allogho, L. H. Pheng, X. K. Nguyen-Le, D. Blouin, and D. Regoli Structure-Activity Studies of B1 Receptor–Related Peptides: Antagonists Hypertension, November 1, 1996; 28(5): 833 - 839. [Abstract] [Full Text] |
||||
![]() |
P. Madeddu, P. P. Parpaglia, M. P. Demontis, M. V. Varoni, M. C. Fattaccio, V. Anania, and N. Glorioso Early Blockade of Bradykinin B2-Receptors Alters the Adult Cardiovascular Phenotype in Rats Hypertension, March 1, 1995; 25(3): 453 - 459. [Abstract] [Full Text] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |